Epic Sciences Raises $40M In Series D Funding

San Diego-based Epic Sciences has raised $40M in a Series D funding, for its cancer testing technology, the company announced Friday morning. According to Epic Sciences, the funding was led by Hermed Capital, and also included Altos Capital Partners, Domain Associates, Genomic Health, Pagoda Investment, Reach Tone Limited, RMI Partners, Sabby Capital and VI Ventures. Epic sciences is developing blood-based tests which help predict drug response in cancer. The company said the fund will go to accelerate clinical studies and enhance its technology. Epic Sciences is led by President and CEO Murali Prahalad, Ph.D. The company has now raised $85.5M in total. More information »